Brind.

Nektar Therapeutics regained full rights to its rezpeg program from Eli Lilly and Company on August 4, 2025.

1 report, 1 independent Updated Aug 4

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Nektar Therapeutics Eli Lilly and Company

Keep exploring

The entities involved

Nektar Therapeutics
American healthcare company

Nothing else this week.
Eli Lilly and Company
American pharmaceutical company
- ExxonMobil, Berkshire Hathaway, and Eli Lilly are top holdings in the Avantis ETF.Mon 17:18
- The FDA approved Olumiant for pediatric indications on September 1, 2026.Mon 05:59

Coverage

Newest first; wire copies grouped

Aug 4ZacksNektar Gears Up to Report Q2 Earnings: What's in the Cards? We expect investors to focus on updates related to Nektar Therapeutics’ NKTR pipeline development activities when the company reports its s